Stelara (ustekinumab) paediatric version launched in the UK to treat psoriasis- Janssen Cilag
Janssen Cilag has launched Stelara (ustekinumab) in the UK. The paediatric indication was approved in Europe in June 2014, after clinical data showed that patients aged 12 to 17 years who were given a standard dose of the drug showed significantly greater improvement in their psoriasis and health-related quality of life compared with placebo after 12 weeks. By conclusion of a 60-week trial, 81.8% patients had reported an adverse event, 5.5% of which were classed as serious but malignancies, opportunistic infections and anaphylactic reactions did not occur.
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.